K. Eschke

A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variants

A single dose of a recombinant murine CMV vaccine expressing SARS-CoV-2 spike protein provides long-lasting immunity against multiple variants in mice.

Macrophages only sense infectious SARS-CoV-2 when they express sufficient ACE2 to permit viral entry, where rapid cytokine responses then limit viral replication.

The paper shows that ACE2-expressing macrophages allow SARS-CoV-2 entry and replication, triggering anti-viral responses, while ACE2-negative macrophages do not support viral entry or cytokine release.

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD mutations

The paper describes the selection of a SARS-CoV-2 neutralizing antibody from COVID-19 patients using phage display, showing it binds the ACE2-RBD interface and remains effective against emerging RBD mutations.

Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants

This paper describes ensovibep, a trispecific DARPin that inhibits SARS-CoV-2 variants by targeting the spike protein, showing potent antiviral activity and protection in animal models.

Rapid SARS-CoV-2 Adaptation to Available Cellular Proteases

This study shows SARS-CoV-2 adapts to Vero E6 cells by losing the furin cleavage motif in spike protein, but retains wildtype sequences, enabling reverse adaptation when passaged on human lung cells.

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface

The paper identifies potent SARS-CoV-2 neutralizing antibodies from pre-pandemic human donors that bind the RBD-ACE2 interface, showing high neutralization efficacy in vitro.